{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:28Z","timestamp":1762300828100,"version":"3.40.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.euo.2024.09.018","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T22:27:43Z","timestamp":1729117663000},"page":"237-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pairing the Right Individual with the Right Regimen: Patient Selection Criteria in the Treatment of Advanced Urothelial Carcinoma"],"prefix":"10.1016","volume":"8","author":[{"given":"David J.","family":"Benjamin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arash Rezazadeh","family":"Kalebasty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.09.018_b0005","doi-asserted-by":"crossref","unstructured":"Mamtani R, Ulloa-P\u00e9rez E, Parikh RB, et al. Real-world uptake of enfortumab vedotin plus pembrolizumab after US Food and Drug Administration approval among patients with advanced urothelial cancer. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2024.08.012.","DOI":"10.1016\/j.eururo.2024.08.012"},{"key":"10.1016\/j.euo.2024.09.018_b0010","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.09.018_b0015","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.euo.2024.02.010","article-title":"The overall survival benefit in EV-302: is enfortumab vedotin plus pembrolizumab the new frontline standard of care for metastatic urothelial carcinoma?","volume":"7","author":"Benjamin","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.09.018_b0020","doi-asserted-by":"crossref","unstructured":"Grande E, Birtle AJ, Kamat AM. Re: Thomas Powles, Bego\u00f1a P\u00e9rez-Valderrama, Shilpa Gupta, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 2024;390:875\u201388. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2024.06.022.","DOI":"10.1016\/j.eururo.2024.06.022"},{"key":"10.1016\/j.euo.2024.09.018_b0025","doi-asserted-by":"crossref","first-page":"e249417","DOI":"10.1001\/jamanetworkopen.2024.9417","article-title":"Treatment patterns and attrition with lines of therapy for advanced urothelial carcinoma in the US","volume":"7","author":"Thomas","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2024.09.018_b0030","doi-asserted-by":"crossref","unstructured":"Apolo AB, Michaels-Igbokwe C, Simon NI, et al. Patient preferences for first-line treatment of locally advanced or metastatic urothelial carcinoma: an application of multidimensional thresholding. Patient. In press. https:\/\/doi.org\/10.1007\/s40271-024-00709-3.","DOI":"10.1007\/s40271-024-00709-3"},{"key":"10.1016\/j.euo.2024.09.018_b0035","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.1990.8.6.1050","article-title":"A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors","volume":"8","author":"Logothetis","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.09.018_b0040","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.09.018_b0045","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.09.018_b0050","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41585-023-00765-8","article-title":"Patient preferences in the treatment of genitourinary cancers","volume":"20","author":"Benjamin","year":"2023","journal-title":"Nat Rev Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T09:51:09Z","timestamp":1744883469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124002281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2588931124002281"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.09.018","relation":{},"ISSN":["2588-9311"],"issn-type":[{"type":"print","value":"2588-9311"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pairing the Right Individual with the Right Regimen: Patient Selection Criteria in the Treatment of Advanced Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}